[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567048":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":22,"locations":29,"responsibleParty":45,"collaborators":47,"id":49,"slug":7,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Haukeland University Hospital","OTHER",null,[9,12],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Blood samples for PK","Blood sampled for pharmacokinetic study",{"type":6,"name":10,"description":13,"armGroupLabels":7,"otherNames":7},"Blood samples before, shortly after infusion of already assigned\u002Fongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.",[15,18],{"name":16,"affiliation":5,"role":17},"Trond T. Serkland, M.D.","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":21},"Silje Skrede, M.D., PhD","University of Bergen","STUDY_DIRECTOR",[23,27],{"name":16,"role":24,"phone":25,"phoneExt":7,"email":26},"CONTACT","004755975563","trond.tretteberg.serkland@helse-bergen.no",{"name":19,"role":24,"phone":7,"phoneExt":7,"email":28},"silje.skrede@helse-bergen.no",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Haukeland University Hospital, Deparment of medical biochemistry and pharmacology","RECRUITING","Bergen","Vestland","5021","Norway",{"type":38,"coordinates":39},"Point",[40,41],5.32415,60.39299,{"lat":41,"lon":40},[44],{"name":16,"role":24,"phone":25,"phoneExt":7,"email":26},{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[48],{"name":20,"class":6},"100567048",false,"NCT06663111","Rituximab and Ocrelizumab in Serum With Multiple Sclerosis","Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)","ROS-MS","Inclusion Criteria:\n\n* Included in OVERLORD-MS (NCT04578639)\n* Willing to attend laboratory for blood sample collection at scheduled time points\n\nExclusion criteria:\n\n\\* Not willing to attend laboratory for blood sample collection at scheduled time points","ALL","18 Years","60 Years",{"count":60,"type":61},60,"ESTIMATED","OBSERVATIONAL","ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.",[65],"Relapsing Remitting Multiple Sclerosis","2024-10-28",{"date":68,"type":69},"2024-10-29","ACTUAL",{"date":71,"type":69},"2021-03-15",{"date":73,"type":61},"2027-12-31",{"name":5,"class":6},1]